UNITED THERAPEUTICS CORPORATION

United Therapeutics will present results from the successful phase 3 TETON-2 study of inhaled treprostinil for idiopathic pulmonary fibrosis at the European Respiratory Society Congress.

United Therapeutics announced that its TETON-2 phase 3 study of nebulized Tyvaso (treprostinil) met its primary endpoint, demonstrating a statistically significant 95.6 mL improvement in absolute forced vital capacity versus placebo in idiopathic pulmonary fibrosis patients.

Liquidia Corporation received $50 million from Healthcare Royalty following the first commercial sale of YUTREPIA and a favorable court ruling denying United Therapeutics' injunction request.

United Therapeutics and Intermountain Health successfully treated the world's first patient with miroliverELAP, a bioengineered external liver assist device, marking the first human clinical trial of a manufactured organ alternative.

United Therapeutics has concluded enrollment of 728 participants in the phase 3 ADVANCE OUTCOMES study evaluating ralinepag, a potential first-in-class once-daily oral prostacyclin agonist for pulmonary arterial hypertension.

United Therapeutics has fully enrolled its Phase 3 TETON 1 study, evaluating nebulized Tyvaso (treprostinil) for idiopathic pulmonary fibrosis (IPF).